Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 12/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 7/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 2/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29794973 | 1.00 | PRMT5 (0.36) | PRMT5WDR77NAAACTSAMAOB | |
| SCHEMBL18151586 | 0.92 | TNF (0.35) | CTSAMAOBMAOATNFUSP30 | |
| SCHEMBL18151436 | 0.83 | MMP3 (0.40) | PRMT5WDR77TNFUSP30 | |
| SCHEMBL18151584 | 0.81 | PIK3CA (0.39) | TNFUSP30 | |
| SCHEMBL18151253 | 0.79 | CYP11B1 (0.43) | PRMT5WDR77TNF | |
| SCHEMBL18159819 | 0.77 | CYP11B1 (0.43) | — | |
| SCHEMBL18151489 | 0.75 | ATM (0.41) | TNF | |
| SCHEMBL18150724 | 0.75 | CYP11B2 (0.47) | TNF | |
| SCHEMBL18150993 | 0.75 | CYP11B1 (0.41) | TNFUSP30 | |
| SCHEMBL16796836 | 0.75 | TNF (0.48) | TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | claimed |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | AVILAR THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-08-28 | — | — | US | disclosed |
| WO-2024098039-A2 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20230087994-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-23 | — | — | US | disclosed |
| CN-115315272-A | Targeting difunctional degradation agent | 耶鲁大学 | 2022-11-08 | — | — | CN | disclosed |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| WO-2016168641-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | SMURF2, SMURF1, MDM2 | PRMT5 784/4885WDR77 1728/4885NAAA 1415/4885 |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | PRMT5 3791/4885WDR77 2429/4885NAAA 3282/4885 |
| US-20230087994-A1 | TARGETED BIFUNCTIONAL DEGRADERS | SMURF2, SMURF1, SSB | PRMT5 765/4885WDR77 1523/4885NAAA 1507/4885 |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | PRMT5 2745/4885WDR77 4618/4885NAAA 3904/4885 |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | IGF2R, M6PR, MSR1 | PRMT5 2567/4885WDR77 1434/4885NAAA 3625/4885 |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | TNF, TNFRSF1A, CD40 | PRMT5 2745/4885WDR77 4618/4885NAAA 3904/4885 |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | PRMT5 2745/4885WDR77 4618/4885NAAA 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.